+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

PCSK9 inhibitors and diabetes mellitus



PCSK9 inhibitors and diabetes mellitus



Vnitrni Lekarstvi 64(12): 1186-1189



Proproteinconvertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor (LDLR) expression. Anti-PCSK9 monoclonal antibody (MAb) therapy reduces LDL-cholesterol (LDL-C) by ~60 % and reduces also the risk of major adverse cardiovascular events. Mendelian randomisation studies showed that patients carrying loss-of-function PCSK9 genetic variants display lower LDL-C and have an increased risk of developing type 2 diabetes (T2DM). Randomized controlled trials with anti-PCSK9 MAbs however showed no effect on the risk. A possible explanation of the discrepancy is that the deficiency of locally but not circulating PCSK9 is responsible for increased LDLR expression in pancreatic islets, which results in cholesterol accumulation and B-cell dysfunction. Thus PCSK9 lowering therapy with MAb targeting mainly circulating PCSK9 might have a limited impact on LDLR expression in pancreatic cells and on the risk of T2DM. Long-term clinical trials are however needed to confirm it. Key words: diabetes mellitus - LDL receptor - PCSK9.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446370

Download citation: RISBibTeXText

PMID: 30704255


Related references

PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?. Herz 41(3): 217-223, 2016

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association 7(13):, 2018

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 41(2): 364-367, 2018

Association of apolipoproteins plasma levels with PCSK9 in type 2 diabetes mellitus. Atherosclerosis 263: E273-E274, 2018

Association of apolipoproteins plasma levels with PCSK9 in type 2 diabetes mellitus. Atherosclerosis 263: E273-E274, 2017

PCSK9 inhibitors and diabetes risk: a question worth asking?. European Heart Journal 37(39): 2990-2992, 2016

PCSK9 inhibitors and diabetes: Translational biology to clinical practice. Diabetes Obesity and Metabolism 21(3): 451-453, 2019

PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. Thrombosis and Haemostasis 119(3): 359-367, 2019

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors. Global Cardiology Science and Practice 2017(2): 13, 2017

The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors. Current Pharmaceutical Design 24(31): 3654-3657, 2018

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 12: Cd005061, 2018

Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 4: Cd012106, 2016

Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 5: Cd012204, 2017

Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Atherosclerosis 280: 14-20, 2019

Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus. Journal of Geriatric Cardiology 13(4): 312-315, 2016